<div id="firstBodyDiv" data-bind-html-content-type="article" data-bind-html-compile="article.body" data-first-article-body="
And stress good news in relation to the signing, where he guessed the two companies earlier, to have the vaccine available in the second half, not the first, of 2021.
She said, “Sanofi” she has the capacity to produce up to one million doses per annum of vaccines listed, and will be capable of supplying up to 360 million doses per annum.
Said John Reid, director of research at “Sanofi” when reporters asked about the time frame for the summary: “we use a dialogue with the regulatory authorities”.
There are currently no vaccines for the Prevention of the virus, which has infected more than 9 million people and killed hundreds of thousands in the world, depends only doctors on certain drugs that have proven useful in helping patients “these 19” on the recovery.
In the shadow of the global race frantically to reach a safe and effective vaccine, said Paul Hudson, CEO of”Sanofi” if “anyone not yet certain of victory” and the development of the plant.
Said about this competition: “there are companies moving faster, but let’s be clear: Speed No 3 cons”, is the experience of the vaccine on the infected with other diseases such as “SARS”, and the possibility not to have the vaccine effective, as well as that the quantities available may not be enough for everyone.
Chief executive officer, said the probability of the success of Sanofi’s “higher than any other”.
Chime these comments with the statements of the president of the medical company “GlaxoSmithKline” who said to”Reuters”, the “company aimed at quality before speed”.
“Sanofi”, which enjoy the Department of vaccines by a good reputation especially in connection with the flu, working on two projects for the production of a vaccine against MERS-CoV, is scheduled to begin clinical trials of the vaccine developed by the with the “Galaxy Jiangsu” in September.
“>
And stress good news in relation to the signing, where he guessed the two companies earlier, to have the vaccine available in the second half, not the first, of 2021.
She said, “Sanofi” she has the capacity to produce up to one million doses per annum of vaccines listed, and will be capable of supplying up to 360 million doses per annum.
Said John Reid, director of research at “Sanofi” when reporters asked about the time frame for the summary: “we use a dialogue with the regulatory authorities”.
There are currently no vaccines for the Prevention of the virus, which has infected more than 9 million people and killed hundreds of thousands in the world, depends only doctors on certain drugs that have proven useful in helping patients “these 19” on the recovery.
In the shadow of the global race frantically to reach a safe and effective vaccine, said Paul Hudson, CEO of”Sanofi” if “anyone not yet certain of victory” and the development of the plant.
Said about this competition: “there are companies moving faster, but let’s be clear: Speed No 3 cons”, is the experience of the vaccine on the infected with other diseases such as “SARS”, and the possibility not to have the vaccine effective, as well as that the quantities available may not be enough for everyone.
Chief executive officer, said the probability of the success of Sanofi’s “higher than any other”.
Chime these comments with the statements of the president of the medical company “GlaxoSmithKline” who said to”Reuters”, the “company aimed at quality before speed”.
“Sanofi”, which enjoy the Department of vaccines by a good reputation especially in connection with the flu, working on two projects for the production of a vaccine against MERS-CoV, is scheduled to begin clinical trials of the vaccine developed by the with the “Galaxy Jiangsu” in September.
– .
